Business Model & Revenue
MetaVia, Inc. (NASDAQ: MTVA) is a clinical-stage biopharmaceutical company headquartered in Raleigh, North Carolina. Formerly known as vTv Therapeutics, the company rebranded to MetaVia to reflect its focus on metabolic diseases.
Pipeline:
- DA-1726: The lead asset — a once-weekly subcutaneously administered oxyntomodulin (OXM) analog that serves as a dual agonist for both GLP-1 and glucagon receptors. Currently in Phase 1 (Part 3, higher-dose cohorts). Indication: obesity and potentially type 2 diabetes. The GLP-1 component suppresses appetite; the glucagon component increases energy expenditure. This dual mechanism could offer advantages over single-agonist GLP-1 therapies.
- Vanoglipel (TTP399): A GPR119 agonist for type 2 diabetes. GPR119 activation increases incretin secretion, improving glucose-dependent insulin release. Vanoglipel has shown synergistic effects with metformin. Currently in mid-stage development.
Revenue model: Zero revenue. The company funds operations through equity financing and potentially future partnership/milestone payments. No commercial products. No collaborations with major pharma companies (as of latest filings).
MetaVia has undergone multiple reverse splits (stock traded at $1.4M/share pre-split). The company has a small team and limited resources relative to its pipeline ambitions. The GLP-1 obesity market represents a massive commercial opportunity, but MetaVia is a David competing against Goliaths (Eli Lilly, Novo Nordisk, Amgen, Viking Therapeutics).
Financial Highlights
Income Statement
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | ($13.85)M | ($13.71)M | ($28.81)M | ($15.89)M |
| R&D | ($6.58)M | ($6.82)M | ($21.55)M | ($9.16)M |
| SG&A | ($7.27)M | ($6.91)M | ($7.26)M | ($6.73)M |
| Operating Income | ($13.85)M | ($13.71)M | ($28.81)M | ($15.89)M |
| Net Income | ($13.09)M | ($12.97)M | ($27.59)M | ($12.47)M |
| FCF | ($15.15)M | ($15.70)M | ($24.72)M | ($10.85)M |
Key Metrics
| Metric | Value |
|---|---|
| Market Cap (post-surge) | ~$8.2M |
| Shares Outstanding | 5.16M |
| Share Dilution (YoY) | +139% |
| Cash (estimated) | ~$15-20M |
| Fein Analyst PT | $20.00 |
| Consensus Rating | Buy |
| 52-Week Range | ~$0.97 - $3.50 |
| All-Time High (pre-split) | $1.4M/share |
| Pipeline Assets | 2 (DA-1726, Vanoglipel) |
| Clinical Stage | Phase 1 |
| Burn Rate (annual) | ~$14M |
The Option Value Math
| Scenario | Probability | Implied Market Cap | Share Price |
|---|---|---|---|
| DA-1726 Phase 2 success + partnership | 10% | $200-500M | $39-97 |
| DA-1726 Phase 2 mixed data | 25% | $30-80M | $6-16 |
| DA-1726 Phase 2 failure | 50% | $5-15M | $1-3 |
| Total pipeline failure | 15% | $1-5M | $0.20-1 |
| Expected Value | — | ~$60M | ~$11.60 |
The expected value calculation suggests the stock is undervalued at $1.58, but this assumes roughly equal probability of each outcome. In reality, the probability of Phase 2 success is likely lower than 10% given the historical failure rate of obesity drugs. The expected value is highly sensitive to the Phase 2 success probability.
Cumulative Losses
| Period | Net Loss |
|---|---|
| FY2025 | ($12.97)M |
| FY2024 | ($27.59)M |
| FY2023 | ($12.47)M |
| FY2022 | ($13.97)M |
| FY2021 | ($15.27)M |
| Total | ($82.27)M |
MetaVia has burned over $82M in five years with zero revenue to show for it.
Competitive Landscape
The GLP-1 obesity/diabetes market is the most competitive therapeutic area in biotech:
- Novo Nordisk (NVO): Semaglutide (Wegovy, Ozempic). The market leader. $30B+ in GLP-1 revenue. Developing amycretin (oral GLP-1/amylin). Deep pipeline, massive commercial infrastructure.
- Eli Lilly (LLY): Tirzepatide (Zepbound, Mounjaro). Dual GIP/GLP-1 agonist. $15B+ in GLP-1 revenue. Developing retatrutide (triple agonist: GIP/GLP-1/glucagon). The most direct competitor to DA-1726's dual agonism approach.
- Amgen (AMZN): MariTide (AMG 133). GLP-1/GIP antagonist-agonist. Phase 2 obesity data showed 20% weight loss at 12 weeks. Massive company with global reach.
- Viking Therapeutics (VKTX): VK2735, a GLP-1/glucagon dual agonist — the most direct comparable to DA-1726. Phase 2 obesity data showed significant weight loss. Market cap ~$3B.
- Structure Therapeutics (GPCR): Oral GLP-1 for obesity. Phase 2 data. Market cap ~$5B.
- Altimmune (ALT), Novo Nordisk (amycretin): Oral GLP-1/amylin programs targeting the oral convenience gap.
MetaVia's position: DA-1726's OXM analog approach is unique but not unprecedented. Viking's VK2735 (GLP-1/glucagon dual agonist) is the closest comparable and trades at a $3B market cap. If DA-1726 shows Phase 2 data competitive with VK2735, MTVA could re-rate to $100-300M market cap — a 12-36x return from current levels. But that's a big "if." The company is years behind Viking, Amgen, and Eli Lilly in clinical development. The massive share dilution history (139% YoY, multiple reverse splits) means current shareholders will own a shrinking fraction of any future success.
Catalysts
-
ADA 2026 presentations (May 2026): Already reported. Three late-breaking posters on DA-1726 and vanoglipel. Drove the +42% surge.
-
DA-1726 Phase 1 Part 3 data: Higher-dose cohort data could show improved weight loss and tolerability. Timeline: 2026.
-
DA-1726 Phase 2 initiation: Moving into Phase 2 would be a major de-risking event. Could attract a pharma partnership.
-
Pharma partnership/licensing deal: If DA-1726 Phase 1 data is compelling, a larger pharma company could partner or license the drug. A partnership would provide capital, credibility, and shared development costs.
-
Q4 2026 data readout: Potential additional clinical data. Timing and specifics TBD.
-
Vanoglipel Phase 2 data: The GPR119 agonist for diabetes provides a secondary catalyst if DA-1726 stalls.
Key risk: The time between now and Phase 2 data (potentially 2027) is a financing risk. The company will likely need to raise capital, causing further dilution.
Key Risks
- Zero revenue. The company is entirely dependent on clinical success of pipeline assets.
- $13.7M annual operating loss. Cash burn is constant and requires continued financing.
- 139% share dilution YoY. The company funds itself by diluting shareholders — this will continue.
- DA-1726 is Phase 1 only. Phase 2 data not expected until 2027. Years from potential commercialization.
- Oxyntomodulin has never been successfully commercialized. Multiple companies have tried and failed with OXM analogs.
- The obesity market is dominated by Eli Lilly (tirzepatide) and Novo Nordisk (semaglutide, amycretin). Competing against $50B+ companies with massive sales forces.
- Stock traded at $1.4M/share pre-split. This company has been reverse-split multiple times — a red flag for long-term shareholders.
- $20 PT from Fein is aspirational. Requires DA-1726 Phase 2 success AND competitive differentiation AND commercial execution — all low-probability events.
- Most clinical-stage obesity drugs fail. The success rate from Phase 1 to approval is ~10-15%.
- No partnership with a major pharma company. MetaVia is going it alone with limited resources.
Our Thesis
MetaVia is a pure pipeline optionality bet. The company has zero revenue and exists solely to develop DA-1726 (obesity) and vanoglipel (diabetes). The ADA 2026 data presentation is a credibility event — it shows the company can generate credible clinical data and present at a top-tier medical conference. But Phase 1 data is a long way from a marketed drug.
The investment thesis rests entirely on DA-1726's potential. Oxyntomodulin is a naturally occurring hormone that hasn't been successfully commercialized despite decades of research — multiple companies have tried and failed. If MetaVia's OXM analog works, the dual GLP-1/glucagon agonism could offer advantages over Wegovy (weight loss via appetite suppression) by adding energy expenditure (glucagon pathway). The key differentiator: DA-1726 is a once-weekly subcutaneous injection with the potential for oral reformulation.
Fein's $20 PT implies a ~$100M market cap — 12x the current level. This requires DA-1726 to show Phase 2 efficacy competitive with or superior to tirzepatide, plus a path to commercialization. The probability is low but not zero. At $8M market cap, the downside is also limited — the company's cash burn is manageable and the ADA presentation extends its credibility window.
This is a lottery ticket on the GLP-1 megatrend. The ticket is cheap ($8M) but the odds are long. Speculative Buy only for capital you can afford to lose completely.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.